公开(公告)号：US20250161281A1

公开(公告)日：2025-05-22

申请号：US18832691

申请日：2023-01-23

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Martin Himmelbauer ,  Zhili Xin ,  Nupur Bansal ,  TeYu Chen ,  John Howard Jones ,  Edward Yin Shiang Lin

IPC: A61K31/439 ,  C07D451/04

Abstract: Provided are compounds of the Formula (I): (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

公开(公告)号：US20250152574A1

公开(公告)日：2025-05-15

申请号：US18837245

申请日：2023-02-13

Applicant: BIOGEN MA INC.

Inventor： Martin Himmelbauer ,  Felix Gonzalez Lopez de Turiso ,  John H. Jones ,  Edward Yin Shiang Lin ,  Robin Prince ,  Vatee Pattaropong ,  Zhili Xin ,  TeYu Chen ,  Nupur Bansal

IPC: A61K31/4709 ,  A61K31/438 ,  A61P25/28 ,  C07D221/20 ,  C07D401/12 ,  C07D491/107

Abstract: Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

公开(公告)号：US20220112216A1

公开(公告)日：2022-04-14

申请号：US17507922

申请日：2021-10-22

Applicant: The Broad Institute, Inc. ,  Biogen MA Inc.

Inventor： Florence Fevrier Wagner ,  Michel Weiwer ,  Arthur J. Campbell ,  Joshua R. Sacher ,  Edward Holson ,  Brian Stuart Lucas ,  TeYu Chen

IPC: C07D513/04 ,  C07D498/04 ,  C07D513/20

Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

公开(公告)号：US20240083900A1

公开(公告)日：2024-03-14

申请号：US18036853

申请日：2021-11-12

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Isaac Marx ,  Jürgen Schulz ,  George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Edward Yin-Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Thomas Purgett ,  Andrew George Capacci ,  Simone Sciabola

IPC: C07D487/04 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: Provided are compounds of Formula (I′): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

公开(公告)号：US20210340107A1

公开(公告)日：2021-11-04

申请号：US17221358

申请日：2021-04-02

Applicant: BIOGEN MA INC.

Inventor： Brian Stuart Lucas ,  Edward Yin Shiang Lin ,  Andrew George Capacci ,  Zhili Xin ,  Istvan Enyedy ,  TeYu Chen ,  John H. Jones ,  Kurt D. van Vloten

IPC: C07D217/04 ,  C07D217/08 ,  C07D217/20 ,  C07D217/22 ,  C07D223/14 ,  C07D311/74 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D413/06 ,  C07D498/04

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US10968181B2

公开(公告)日：2021-04-06

申请号：US16473667

申请日：2017-12-27

Applicant: BIOGEN MA INC.

Inventor： Brian Stuart Lucas ,  Edward Yin-Shiang Lin ,  Andrew George Capacci ,  Zhili Xin ,  Istvan Enyedy ,  TeYu Chen ,  John H. Jones ,  Kurt D. van Vloten

IPC: C07D311/76 ,  C07D217/04 ,  C07D217/08 ,  C07D223/16 ,  C07D498/14 ,  A61K31/352 ,  A61K31/47 ,  C07D217/20 ,  C07D217/22 ,  C07D223/14 ,  C07D311/74 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D413/06 ,  C07D498/04

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20250090524A1

公开(公告)日：2025-03-20

申请号：US18709268

申请日：2022-11-11

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  BIn Ma ,  Jürgen Schulz ,  Marta Nevalainen ,  TeYu Chen ,  Robin J. Prince ,  Harold George Vandeveer ,  Issac Marx ,  Simone Sciaboba ,  Edward Yin Shiang Lin

IPC: A61K31/4985 ,  A61K31/437 ,  A61K31/55 ,  C07D471/04 ,  C07D487/04

Abstract: Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables in Formula (I) are as defined herein; and methods for their use and production.

公开(公告)号：US20250034150A1

公开(公告)日：2025-01-30

申请号：US18709273

申请日：2022-11-10

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Jürgen Schulz ,  Marta Nevalainen ,  TeYu Chen ,  Robin Prince ,  Harold George Vandeveer ,  Isaac Marx ,  Simone Sciabola ,  Zain Yousaf

IPC: C07D487/04 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  C07D471/04 ,  C07D519/00

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables in Formula (I) are as defined herein; and methods for their use and production.

公开(公告)号：US20240327380A1

公开(公告)日：2024-10-03

申请号：US18019540

申请日：2021-08-05

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  Harold George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Rab Gilfillan ,  Edward Yin Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Bin Ma

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

CPC classification number: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

公开(公告)号：US20230121818A1

公开(公告)日：2023-04-20

申请号：US17788127

申请日：2020-12-23

Applicant: BIOGEN MA INC.

Inventor： Bin Ma ,  Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Andrew George Capacci

IPC: C07D401/14 ,  C07D413/12 ,  C07D471/04 ,  C07D403/12 ,  C07D403/10 ,  C07D495/04 ,  C07D401/12 ,  C07D413/14

Abstract: Provided are compounds of Formula (I′) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R8, R9, R11A, R11B, R12, Ri, Rii, A1, A2, Q1, Q2, Q3, X, W, and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.